Our top pick for
Novan Inc is a biotechnology business based in the US. Novan shares (NOVN) are listed on the NASDAQ and all prices are listed in US Dollars. Novan employs 23 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.13|
|52-week range||$4.35 - $25.90|
|50-day moving average||$8.13|
|200-day moving average||$9.83|
|Wall St. target price||$36.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.06|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-16)||N/A|
|1 month (2021-09-27)||-15.12%|
|3 months (2021-07-27)||-11.21%|
|6 months (2021-04-27)||440.15%|
|1 year (2020-10-27)||1,324.58%|
|2 years (2019-10-25)||194.63%|
|3 years (2018-10-26)||202.12%|
|5 years (2016-10-27)||20.8999|
|Revenue TTM||$4 million|
|Gross profit TTM||$-3,907,000|
|Return on assets TTM||-28.65%|
|Return on equity TTM||-185.91%|
|Market capitalisation||$136.6 million|
TTM: trailing 12 months
There are currently 462,962 Novan shares held short by investors – that's known as Novan's "short interest". This figure is 8.8% down from 507,791 last month.
There are a few different ways that this level of interest in shorting Novan shares can be evaluated.
Novan's "short interest ratio" (SIR) is the quantity of Novan shares currently shorted divided by the average quantity of Novan shares traded daily (recently around 445155.76923077). Novan's SIR currently stands at 1.04. In other words for every 100,000 Novan shares traded daily on the market, roughly 1040 shares are currently held short.
However Novan's short interest can also be evaluated against the total number of Novan shares, or, against the total number of tradable Novan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novan's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Novan shares in existence, roughly 20 shares are currently held short) or 0.0248% of the tradable shares (for every 100,000 tradable Novan shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novan.
Find out more about how you can short Novan stock.
We're not expecting Novan to pay a dividend over the next 12 months.
Novan's shares were split on a 1:10 basis on 25 May 2021. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novan shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Novan shares which in turn could have impacted Novan's share price.
Over the last 12 months, Novan's shares have ranged in value from as little as $4.35 up to $25.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novan's is 0.0661. This would suggest that Novan's shares are less volatile than average (for this exchange).
Novan, Inc. , a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co. , Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.